Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131469 · ClinicalTrials.gov registry record · Phase 4
Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta
A Phase 4 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 79
- Enrollment target
NCT00131469: Completed Phase 4 study, sponsored by Oregon Health and Science University.
NCT00131469 is a Phase 4 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 79 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00131469, a Phase 4 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 79 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of teriparatide (FORTEO), which is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in adults affected with Osteogenesis Imperfecta (OI).
Primary Outcome
bone density by dual energy xray absorptiometry
Interventions
- DRUG Placebos
- DRUG Teriparatide (FORTEO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2005-06 |
| Est. Completion | 2011-01 |
| Phase | Phase 4 |
What the finished NCT00131469 record still lists
NCT00131469 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT00131469 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00131469 about?
NCT00131469 is a clinical study titled "Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta". The purpose of this study is to determine the effectiveness of teriparatide (FORTEO), which is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in adults affected with Osteogenesis Imperfecta (OI).
What is the current status of trial NCT00131469?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 79 participants. The study started on 2005-06. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00131469?
The interventions under investigation include: Placebos (DRUG), Teriparatide (FORTEO) (DRUG).
Who is sponsoring clinical trial NCT00131469?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00131469's enrollment target sits among peer trials
79 980th of 2000 higher than 1,019 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia